The U.S. Food and Drug Administration has accepted CytomX Therapeutics and Bristol-Myers Squibb’s joint Investigational New Drug application (IND). The application is for a CTLA-4-directed Probody therapeutic, the first target to advance into the clinic under the companies’ strategic collaboration formed in May 2014.    That partnership was expanded in March 2017, taking total upfront payments to CytomX to $275 million. In return, the collaboration provided Bristol-Myers Squibb with the ...